Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
=== America's "first opioid crisis" === The 1880s saw opiate addiction surge among housewives, doctors, and Civil War veterans, creating America's "first opioid crisis". By the end of the century, an estimated one in 200 Americans were addicted to opiates, 60% of them women, typically white and middle- to upper-class. Medical journals of the later 1800s were replete with warnings against overprescription. As medical advances presented better treatment options, prescribed opiate use began to decline. Meanwhile, opium smoking remained popular among Chinese immigrant laborers, thousands of whom had arrived during the California gold rush. The public face of opiate use began to change, from affluent white Americans, to "Chinese, gamblers, and prostitutes". During this period, states and municipalities began enacting laws banning or regulating certain drugs. In Pennsylvania, an anti-morphine law was passed in 1860. In 1875, San Francisco enacted an anti-opium ordinance, vigorously enforced, imposing stiff fines and jail for visiting opium dens. The rationale held that "many women and young girls, as well as young men of a respectable family, were being induced to visit the Chinese opium-smoking dens, where they were ruined morally and otherwise." The law catered to resentment towards the Chinese laborer population who were being accused of taking jobs; other uses of opiates or other drugs were unaffected. Similar laws were enacted in other states and cities. The federal government became involved, selectively raising the import tariff on the smoking grade of opium.
Member of the State Committee on Vocational Education (1948–1951) Member of numerous committees for the foundation of new industries in postwar Greece (throughout the 1950s) First Vice-President of the National Hellenic Research Foundation (1958–1968), of which he was a key founder Minister of Industry in the Paraskevopoulos technocratic caretaker government (1963–1964) President of the Greek Atomic Energy Commission (1964–1965) The democratic ideals of Zervas made him a target of the military junta established in 1967, which removed him from his position in the University of Athens in 1968 after almost three decades of dedicated research and teaching. In response, the Academy of Athens of which Zervas had been a member since 1956 elected him as its president in 1970. After his term as President of the Academy, Zervas retired in 1971.
10-Methacryloyloxydecyl dihydrogen phosphate (10-MDP, MDP Monomer) is a chemical compound used in dental adhesive materials. This organophosphate monomer was developed in 1981 by the Japanese company Kuraray for the preparation of dental adhesion polymers
==== 5-HT2 receptor ==== Antagonism of the 5-HT2 subfamily of receptors and inverse agonism of the 5-HT2C receptor appears to be in part responsible for mirtazapine's efficacy in the treatment of depressive states. Mirtazapine increases dopamine release in the prefrontal cortex. Accordingly, it was shown that by blocking the α2-adrenergic receptors and 5-HT2C receptors mirtazapine disinhibited dopamine and norepinephrine activity in these areas in rats. In addition, mirtazapine's antagonism of 5-HT2A receptors has beneficial effects on anxiety, sleep and appetite, as well as sexual function regarding the latter receptor. Mirtazapine has been shown to lower drug seeking behaviour (more specifically to methamphetamine) in various human and animal studies. It is also being investigated in substance abuse disorders to reduce withdrawal effects and improve remission rates. Mirtazapine significantly improves pre-existing symptoms of nausea, vomiting, diarrhea, and irritable bowel syndrome in affected individuals. Mirtazapine may be used as an inexpensive antiemetic alternative to Ondansetron. In conjunction with substance abuse counseling, mirtazapine has been investigated for the purpose of reducing methamphetamine use in dependent individuals with success.
Sources: en.wikipedia.org
=== Graphic content === In June 2021, TikTok made an apology after a shock video, showing a girl dancing which then cuts to a graphic scene of a man being beheaded by a saw, went viral. The video has been put on TikTok's blacklist, which detects it before being uploaded. TikTok has previously worked to remove graphic content from its platform, including a suicide video that circulated in September 2020, which had appeared among the recommended clips of TikTok's For You section.
=== Category:EC 1.12 (act on hydrogen as a donor) === Category:EC 1.12.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.12.2 (with a cytochrome as acceptor) Category:EC 1.12.5 (with a quinone or similar compound as acceptor) Category:EC 1.12.7 (with an iron–sulfur protein as acceptor) Category:EC 1.12.98 (with other known acceptors) Category:EC 1.12.99 (with other acceptors)
Several antibiotics exert their action by targeting the translation process in bacteria. They exploit the differences between bacterial and eukaryotic translation mechanisms to selectively inhibit protein synthesis in bacteria without affecting the host.
== History == Dei BioPharma was established in 2014 by Ugandan scientist and entrepreneur Dr. Matthias Magoola. Its flagship facility, situated on 150 acres in Matugga, was inaugurated in July 2021 by Ugandan President Yoweri Museveni and then Kenyan Deputy President William Ruto.
The first epitope-based vaccine was developed in 1985 by Chaim Jacob and colleagues from The Weizmann Institute of Science. Epitope-based vaccines stimulate humoral and cellular immune responses using isolated B-cell or T-cell epitopes. These vaccines can use multiple epitopes to increase their efficacy. To find epitopes to use for the vaccine, in silico mapping is often used. Once candidate epitopes are found, the constructs are engineered and tested for vaccine efficiency. While epitope-based vaccines are generally safe, one possible side effect is cytokine storms.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.